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Imiquimod Enhances the Systemic Immunity Attained
by Local Cryosurgery Destruction of Melanoma
Lesions
Pedro Redondo1, Julio del Olmo1, Ascensio´n Lo´pez-Diaz de Cerio2, Susana Inoges2, Miren Marquina1,
Ignacio Melero3 and Maurizio Bendandi2
Melanoma lesions can be frozen in vivo, resulting in necrotic death of malignant cells and in tumor antigen
release suitable for cross-presentation by professional antigen-presenting cells. Imiquimod is a small molecule
with adjuvant pro-inflammatory effects that can be topically delivered as a cream. Local cryosurgery of B16/
ovalbumin (OVA)-derived subcutaneous tumor nodules leads to curative destruction of the lesions. If
imiquimod is repeatedly applied on the cryo-treated lesion, a conspicuous, leukocyte-rich inflammatory
infiltrate appears during the days following treatment. Mice treated by cryosurgery plus imiquimod rejected
rechallenges of B16/OVA in 90% of the cases, whereas cryosurgery alone failed to prevent tumor grafting in 70%
of the cases. The combination treatment of B16/OVA tumors was also able to protect 60% of the mice against
outgrowth of a lethal dose of non-transfected B16 tumor cells. Addition of imiquimod to cryosurgery results in
increases of the cellular immune response against tumor antigens as measured by in vitro IFN-g production and
T-cell proliferation in response to OVA. The potent memory response is not only directed against the OVA
epitope, but also toward a broader range of B16 antigens. Our data indicate that these combined treatments
turn the treated tumor lesion into an autologous tumor vaccine, which is even able to cause vitiligo in several
cases. These preclinical data and the simplicity of the procedures warrant the design of a pilot clinical trial.
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INTRODUCTION
In situ tumor destruction with several techniques has received
increasing attention as a minimally invasive option for local
management of cancer. As a result of in situ cancer cell
destruction, large amounts of tumor debris are released and
they could be potentially taken up by immune-system cells.
For long it has been discussed whether this tumor debris is
able to induce a systemic immune response and it has been
demonstrated that maturation of antigen-presenting cells,
especially dendritic cells (DCs), is a prerequisite for the
induction of adaptive immunity (De Vries et al., 2003).
Cryoablation, or destruction of tissue by freezing, has long
been recognized as a potential tool in the treatment of cancer
(Gage et al.,1998). Cryosurgery has been successfully used
for the ablation of skin, prostate (Cohen, 2004), kidney (Gill
et al., 2005), bone (Bickels et al., 1999), and liver tumors
(Seifert and Junginger, 2004), as well as for treatment of
locally advanced breast malignancies (Kaufman and Rew-
castle, 2004) and even fibroadenomas (Littrup et al., 2005).
Besides local destruction of the primary tumor, it has been
claimed that cryoablation is sometimes able to induce
systemic antitumor immune responses. Several case reports
mention a reduction of metastatic disease after cryoablation
of the primary tumor (Gage, 1969; Soanes et al., 1970).
Moreover, together with its local destructive effect, cryosur-
gery also leads to an inhibition of secondary and metastatic
tumor growth compared with surgical excision (Joosten et al.,
2001).
Tumor cryoablations release large amounts of tumor
antigens in the form of necrotic tumor cells and cellular
debris, and enhance migration of DCs from the tumor site to
the draining lymph nodes (Sauter et al., 2000; Gazzaniga
et al., 2001). Cryoablation induces both a tumor-specific
T-cell response in the tumor draining lymph nodes and an
increased systemic natural killer (NK) cell activity, which
correlates with rejection of tumors on rechallenge. This
immunologic response is clearly limited and it may be
necessary to augment it by adding an adjuvant (Sabel et al.,
2005). A recent paper has shown the systemic antitumor
immune effect of tumor cryosurgery combined with sub-
sequent in situ injection of autologous unmodified immature
DCs (Machlenkin et al., 2005). According to other reports, it
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is useful to either administer a blocking monoclonal antibody
against cytotoxic T-lymphocyte-associated antigen 4 (den
Brok et al., 2004), the toll-like receptor (TLR)9-ligand CpG-
ODN (den Brok et al., 2006), or an immunotheraphy with
IL-2 and GM-CSF (Ito et al., 2003) at the time of local tumor
destruction.
Imiquimod is an immunomodulatory, small-molecule
compound in the imidazoquinoline family that displays both
antiviral and antitumor effects through TLR-7 (Hemmi et al.,
2002). As a TLR-7 agonist, imiquimod stimulates immature
plasmacytoid DCs (pDCs). Through the induction of the
surface expression of costimulatory molecules such as CD40,
CD80, and CD86, as well as through the production and
release of specific cytokines, especially IFN-a, TNF- a, and
IL-12, imiquimod-treated DCs induce type-1 T-helper im-
munity. Imiquimod in the treatment of primary (melanoma
lentigo maligna) or metastatic melanoma has been used
previously (Ahmed and Berth-Jones, 2000; Steinmann et al.,
2000).
In this report, we tested whether adjunctive treatment with
the TLR-7 agonist imiquimod could augment antitumor
immune responsiveness in B16/ovalbumin (OVA) tumor mice
treated with cryosurgery. Mice that received either imiqui-
mod alone or cryosurgery alone were partially protected from
tumor development. Strikingly, mice that received cryosur-
gery and topical imiquimod were protected even from a
subsequent tumor cell challenge.
RESULTS
Development of an in situ tumor ablation model
To investigate the induction of antitumor immune responses
following in situ tumor destruction, we developed a mouse
B16/OVA model in which cryosurgery was used to destroy
established tumors. On day 10 after tumor inoculation on the
flank, B16/OVA tumors were treated either by cryosurgery or
excision. Non-treated mice developed large tumor burdens
by day 20 of tumor growth, at which time the mice were
killed for analysis. Efficacy of cryosurgery was judged by the
occurrence of local recurrence during all further experiments
described. Local recurrence after cryosurgery was observed
only in 5% of the mice (Figure 1), compared with 20% of
recurrences observed after tumor excision.
Effect of cryosurgery and tumor excision
The effect of cryosurgery of the primary tumor on the growth
rate of the second tumor in the flank was determined and
compared with excisional treatment. A detailed time
schedule of the different treatments is given in Figure 1.
Rechallenge was given 15 days after cryosurgery. In
some experiments, because of the occurrence of local
recurrences in several mice treated with surgical excision,
age-matched, untreated naı¨ve mice were used as control. As
shown in Figures 1 and 2, cryosurgery of B16/OVA resulted
in a clear delay in the outgrowth of B16/OVA tumor cells and
in a low level of protection (25–30% of the mice). On the
contrary, a rechallenge with the less immunogenic B16F10
melanoma cell line (3 104) 15 days after cryosurgery
resulted in all mice developing tumors, with some delay
compared with controls, but with no protection whatsoever
(data not shown).
Effect of topical imiquimod
Topical imiquimod treatment without cryosurgery was
not sufficient to eradicate either the primary tumor or a
tumor rechallenge. The clinical response of the melanoma
to imiquimod depends on the size of the tumors at
the beginning of treatment. When tumor size at the beginning
of the experiment was 4150 mm3, all mice treated
with imiquimod showed progressive disease. A partial
response was noted instead when topical imiquimod
was begun at the same time of tumoral cell injection (data
not shown).
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Figure 1. Experiment design, local recurrence, and survival. (a) Time
schedule outlining the different treatments used in the experiments. Ten days
after tumor injection, B16/OVA melanoma tumors (6–8 mm) were treated with
cryosurgery. Fifteen days after cryosurgery mice were rechallenged. (b) Local
recurrence of B16/OVA tumors after cryosurgery. (c) Cryosurgery of B16/OVA
tumors resulted in a clear delay in the outgrowth of tumors after rechallenge
with B16/OVA tumor and in a low level of protection (25% of the mice),
compared with either mice undergoing surgical excision or control naı¨ve
mice.
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Topical application of imiquimod induced skin inflamma-
tion with increased number of inflammatory cells in the
dermis. Histochemistry systemically revealed a large sub-
cutaneous population of infiltrating leukocytes (data not
shown). Mice that had been treated daily with imiquimod for
10 days presented a pronounced splenomegaly, compared
with the normal spleens of either naive or untreated mice
with tumor (data not shown).
Effect of cryosurgery and topical imiquimod
Following the same time schedule of Figure 1, we explored
whether in situ tumor destruction in combination with topical
imiquimod could enhance the antitumor immunity in our
model. Imiquimod or placebo cream was applied once a day
to the skin of the mice the day of and during 9 days after
cryosurgery. Fifteen days later, mice were challenged in the
contralateral back with a lethal dose (3 104 cells) of the
B16/OVA tumor. The combination of cryosurgery and
imiquimod treatment resulted in the protection against such
a lethal dose in 80–90% of the mice (Figure 2). Mice treated
with cryosurgeryþ imiquimod that had rejected the first B16/
OVA tumor challenge were completely protected against a
second B16/OVA tumor rechallenge (105 cells) 90 days later.
In comparison, all cryosurgery-treated mice developed
second tumors (Figure 3).
To study the immune response against antigens other than
OVA protein, we used the poorly immunogenic B16F10
melanoma cell line. We investigated whether the cryosurger-
yþ imiquimod-treated mice that had rejected the previous
rechallenge with B16/OVA tumor were protected against a
third rechallenge with a lethal dose of B16F10 (3104). Six
out of 12 mice from the group that underwent local
cryosurgery and topical imiquimod treatment were alive at
day 160 following three rechallenges, whereas no mice from
any other group survived at that time point (Figure 3). A fourth
rechallenge with 2 105 B16F10 cells was ultimately lethal
to all survivors, although a delayed outgrowth of the B16F10
tumor was also observed compared with controls (data not
shown).
In summary, only mice that were treated in situ by
cryosurgery and topical imiquimod had a statistically
significant survival advantage (Po0.0001) in comparison
with untreated. This combination treatment induces a potent
memory response, which is not only directed against the
OVA epitope, but also toward a broader range of B16
antigens.
Inflammatory infiltrates in the treated and rejected tumors
The pathology study of primary tumors showed no differences
between cryosurgeryþ imiquimod-treated mice and cryo-
treated mice or between imiquimod-treated mice and
controls. An intense infiltrative response consisting of
polymorphonuclear leukocytes around the tumor was de-
tected 24 hours after cryosurgery. At day 7, tumor tissue
was completely replaced by necrotic masses and fibrosis
(Figure 4).
The pathology study of secondary tumors growing after
rechallenge also showed no relevant differences among all
mice groups. In a subsequent experiment, we indelibly
marked the administration site of B16/OVA tumor rechal-
lenge and 48 hours later it was analyzed from a histological
standpoint in all mice groups (i.e., those respectively treated
with imiquimod, cryosurgery, the combination of both, and
controls). Remarkably, as no infiltrating neutrophils were
seen in controls, such an infiltration was conspicuously more
pronounced in mice treated with combination treatment,
compared with either therapy option alone. Indeed, only in
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Figure 2. Kaplan-Meier Survival. The same time schedule of Figure 1 was
used. Mice with B16/OVA tumors (6–8 mm) were treated with cryosurgery.
At the same time, mice were topically treated with imiquimod or vehicle
cream for 10 days. Fifteen days later, a rechallenge with 3 104 B16/OVA
cells was given in the contralateral flank. Survival curve shows 90%
protection of melanoma outgrowth after combined treatment with
cryosurgery and imiquimod (Po0.0001) (n¼ 8–10). Five age-matched
untreated naı¨ve mice were used as a control. One representative experiment
of three independent experiments is shown. Mice in the topical imiquimod
group were killed as soon as primary tumor volume reached 1,500 mm3, with
no sign of protection against rechallenge, and died with an average survival
time overlapping to that of the control group (data not shown).
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Figure 3. Survivors of experiments of Figure 2 after several rechallenges,
according to the time schedule outlining the different treatments as used in
the experiments. Five age-matched, untreated naı¨ve mice were used as
control for each rechallenge. To test the induced tumor resistance, 12 of the
cured mice were repeatedly rechallenged (up to three times) with different
tumor dose levels, (day 90, second rechallenge with 105 B16/OVA; day 120,
third rechallenge with 3 104 B16F10; day 160, fourth rechallenge with
2 105 B16F10, data not shown). Seventy-five percent protection was
observed in mice rechallenged with B16/OVA (cryosurgeryþ imiquimod
group). Surviving mice were rechallenged with 3 104 B16F10 cells on the
controlateral flank, with a 66% protection rate at day þ 160 for mice initially
treated with the combination of cryosurgery and imiquimod.
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lesions from mice treated with the combination of cryosur-
gery and imiquimod we were able to detect a massive
neutrophil infiltrate, even with signs of tumor cell lysis
(Figure 4). To establish whether such an inflammatory
response may be specifically directed against the OVA
protein, we repeated this experiment following a rechallenge
with B16F10 cells. The results were virtually identical,
proving that leukocyte infiltration secondary to combination
treatment also targets B16 cell line antigens different from
OVA protein.
Vitiligo
Cryosurgery induced localized vitiligo at the site of tumor
implantation in 80% of mice. Cryosurgery associated with
topical imiquimod induced localized and generalized vitiligo
in several mice (Figure 5). This finding had not been observed
in experiments with imiquimod alone and indicates that the
effects of imiquimod can be seen systemically when used as
an adjuvant to cryosurgery.
Proliferation assay and measurement of cytokine production
To analyze the immune response induced after either tumor
cryoablation or cryosurgery plus imiquimod treatment, we
performed a proliferation assay. Lymphocytes were plated in
96-well plates alone or with 10 mM of OVA.
In Figure 6a, the stimulation index is comparatively
given according to treatment groups. Lymphocytes from
control animals did not proliferate in the presence of OVA
protein. Vice versa, lymphocytes from treated animals
proliferated in response to OVA protein, although with
a relatively weak stimulation index. Moreover, the
stimulation index of lymphocytes from mice treated
with cryosurgery was lower than that of those treated with
cryosurgeryþ imiquimod.
In Figure 6b, data on IFN-g production when lymphocytes
are stimulated in vitro with either OVA protein or culture
medium as a control are comparatively given according to
treatment groups. IFN-g production is lower in mice treated
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Figure 4. Hematoxylin–eosin staining of representative mice. (a) Untreated tumor control with well-defined tumor areas, at day 2. (b) Tumor treated with
cryosurgery. Extensive intratumoral necrotic area and surrounding fibrotic tissue with a massive leukocyte infiltration at day 7. (c) Neutrophil infiltration around
a tumor nest in a cryosurgery-treated mouse. (d) Massive chemotaxis and B16/OVA tumor cell destruction in a mouse treated with the combination of
cryosurgery and imiquimod. (e) Massive chemotaxis and B16F10 tumor cell destruction in a mouse treated with the combination of cryosurgery and imiquimod.
(f) Higher magnification of the area boxed in (e), showing an intense neutrophil infiltrate. (c–f) are based on a rechallenge removed 48 hours after its
implantation. (a, c, d, and e) original magnification  200; (b) original magnification  100; (f) original magnification  1000.
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Figure 5. Vitiligo in treated mice. (a) Cryosurgery induced localized vitiligo
at the application site. (b) In several mice, cryosurgery associated with topical
imiquimod induced both localized and distant site vitiligo.
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with cryosurgery than in those treated with cryosurgery
þ imiquimod.
Assay of NK cell activity and CTL responses
Neither NK cell activity nor CTL responses were observed in
any mice treatment group (data not shown).
DISCUSSION
Metastatic melanoma of the skin is extremely difficult to
treat. Despite a variety of available options including surgery,
immunotherapy, chemotherapy, X-ray therapy, regional
hyperthermia, and carbon dioxide laser ablation treatment
is often unsuccessful. DC vaccination has been shown to
evoke tumor-specific responses in several patients with
melanoma (Nestle et al., 1998), although in many cases
these ex vivo-generated DC are ineffective to cure patients
with established melanoma. Melanocytes are sensitive to
low temperatures and cryosurgery has been proposed as
an alternative to melanoma surgery. However, recurrence
rates up to 50% are reported (Gaspar and Dawber, 1997);
this fact may be partly explained by extension of malignant
melanocytes down hair follicles and other dermal appen-
dages, where they are relatively protected from the effects
of cryosurgery. Cryosurgery exerts damage effect on tumor
cells, including but not limited to disruption of metabolic
pathways, conversion of the lipid layers of the cell membrane
into semisolids, breakdown of the cytoskeletal microtubular
networks, exposure of the cells to a hyperosmotic environ-
ment, and the grinding action of irregular ice formations. In
our hands, although a tumor-specific immune response was
observed when leaving the tumor frozen, mice were weakly
protected against a tumor rechallenge (25–30%).
To increase antitumor immunity following cryosurgery,
we explored the stimulation of TLR7 by imiquimod.
Imiquimod (1-(2-methylpropyl)-1H-imidazol (4,5-c)quinolin-
4-amine) is an imidazoquinoline compound that is currently
approved for the treatment of genital human papillomavirus
infection, basal cell carcinoma, and actinic keratoses.
Recently, significant interest has developed in the use of
imiquimod for lentigo maligna and metastatic malignant
melanoma (Ahmed and Berth-Jones, 2000; Steinmann et al.,
2000). Several patients with skin melanoma metastases or in
situ melanoma have been treated with imiquimod under
different protocols, with complete or almost complete
clinical and pathological remission in all cases (Steinmann
et al., 2000; Vereecken et al., 2003; Wolf et al., 2003).
However, contradictory results have also been reported
(Ugurel et al., 2002; Fisher and Lang, 2003). Imiquimod
induces apoptosis in malignant melanoma cells in a rather
tumor-selective manner both in vitro and in vivo (Schon
et al., 2004). The proapoptotic activity of imiquimod is
independent of membrane-bound death receptors, whereas it
depends on Bcl-2 expression, as demonstrated by over-
expression of Bcl-2 in melanoma cells. The application
of imiquimod in modifying the expression of metalloprotei-
nases, promoting the expression of their inhibitors and
modifying the expression of genes involved in angiogenesis,
could potentially create a local microenvironment unfavor-
able for tumor expansion (Hesling et al., 2004). Despite
the striking clinical effect in our experiments, we did not
see any specific action of imiquimod directly involving tumor
biology. However, when the cryoablation of established
B16/OVA tumors was combined with topical imiquimod
administration, potent antitumor immune responses
were induced. Intriguingly, the combination treatment of
B16/OVA tumors was also able to protect 60% of the
mice against outgrowth of a lethal dose of B16F10 tumor.
These results indicate the simultaneous induction of re-
sponses against multiples epitopes and not only against the
OVA protein. The combination of sharp excision with
imiquimod was not examined because the hypothesis holds
that only cryo-induced tissue destruction would make tumor
antigens sufficiently available for an enhanceable immune
response.
Theoretically, the mechanism responsible for the induc-
tion of antitumor immunity following combination treatment
with cryosurgery and imiquimod should be related to DCs. In
human skin, epidermal Langerhans’ cells and dermal DCs
continuously monitor the antigenic environment and any
encounter with damaged tissue induces their activation and
migration to the draining lymph nodes. The expression of
TLR7 in mice is considerably different from humans, allowing
direct dermal DCs and Langerhans’ cell activation in the
mouse. Topical cutaneous application of the TLR7 imiqui-
mod can induce the maturation and migration of cutaneous
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Figure 6. Characterization of immune response induced after different
treatments. Animals from different groups were killed and lymph node
removed. Lymphocytes were stimulated in vitro alone or with OVA protein.
Supernatants were collected to measure IFN-g production and cells pulsed
with [3H] thymidine for proliferation assay. Thymidine incorporation was
determined and the stimulation index calculated. (a) The stimulation index is
comparatively given according to treatment groups. (b) Data on IFN-g
production when lymphocytes are stimulated in vitro with either OVA protein
or culture medium as a control.
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DCs. It has recently been shown that topical imiquimod leads
to Langerhans’ cell maturation and their migration to draining
lymph nodes (Burns et al., 2000; Suzuki et al., 2000).
In humans, the molecule first acts through pDC. Palamara
et al. (2004) showed an increase of pDCs in spleen and skin
of both normal mice and mice with melanoma treated with
imiquimod. The number of these cells correlates well with
the clinical response of the tumors to the drug, being higher
in responders. They proposed that the antitumor properties of
imiquimod are related, at least in part, to the recruitment of
pDCs and to the release of IFN-a by these cells. Human pDCs
are found in blood and secondary lymphoid organs (Yang
et al., 2005), express only TLR-7 and TLR-9 (Kadowaki et al.,
2001), and appear to have a role in the clinical response to
imiquimod. pDCs are recruited to cutaneous epithelial and
lymphoproliferative tumors treated with imiquimod and they
are the primary source of IFN-a in skin lesions in response to
imiquimod treatment (Urosevic et al., 2005).
Topical application of imiquimod following tumor cryo-
surgery may thus be aimed at enhancing DC activation, but
also at activating other cells, such as neutrophils. In
particular, although apparently documenting only a modest
involvement of direct T-cell immunity, our studies demon-
strate an essential role for neutrophils during the first 48 hours
after treatment, at least when it comes to efficaciously
counter rechallenges. Furthermore, inflammatory infiltration
features were virtually identical when B16F10 was used to
rechallenge, proving that the overall response is not limited to
OVA. Although the exact meaning of such an infiltration
remains elusive, it has to be considered as sufficiently
efficacious as to impede tumor development after rechal-
lenge. Probably it will require gene microarray analysis to
understand better how the inflammatory process differs
between sharp excision, thermal damage, and thermal
damage plus TLR agonism.
In a recent paper, DCs were activated in vivo by injecting
immature cells into a cutaneous site that had been treated
with topical imiquimod (Nair et al., 2003). Imiquimod may
enhance immune response to vaccination (Shackleton et al.,
2004) and should be considered in the design of future
clinical trials that seek to optimize DC-based immunothe-
rapy. Recent evidence suggests that persistent TLR signaling
may help in bypassing regulatory T-cell-induced tolerance
(Yang et al., 2004), enhancing autoimmune T-cell respon-
siveness (Lang et al., 2005), or even reversing regulatory
T-cell function (Pulendran, 2004; Prins et al., 2006).
Clinical interest in the in situ destruction of melanoma has
resurfaced (Ito et al., 2003; den Brok et al., 2004, 2006;
Machlenkin et al., 2005). Tumor cells are weakly immuno-
genic and even produce factors that suppress cellular
immunity. Methods to enhance the immunogenicity of tumor
cells might improve the clinical efficacy of cryosurgery. If the
cryoablation of cutaneous melanoma associated with topical
imiquimod can induce an antitumor immune response
capable of reducing both local and distant recurrence, then
this approach may be even superior to surgical excision.
Further studies are warranted to assess the potential of this
combination for treating melanoma.
MATERIALS AND METHODS
Mice
C57BL6/J mice were purchased from the Jackson laboratory (Charles
River laboratories, Barcelona, Spain). Animal care was carried
out in accordance with our institutional guidelines. For tumor
experiments, female 7–9-week-old mice with an average weight
of approximately 20 g were used. Mice were acclimatized and
after 1 week under observation they were caged in groups of five
or 10 and their back was shaved. The B16-F10 cell line was obtained
from the American Type Culture Collection. B16-F10 cells
transfected to express chicken OVA have been described previously
(B16/OVA) (Dobrzanski et al., 1999). All experiments were
done according to the guidelines for animal care of the Center
for Applied Pharmacological Research (University of Navarra,
Pamplona, Spain).
Tumors
Mice were injected subcutaneously in the middle of the right flank
with 3 105 B16/OVA cells. Cells were cultured in RPMI 1640
medium (Invitrogen Life Technologies, Renfrew, UK), supplemented
with 10% fetal calf serum, harvested and injected in 100 ml of
phosphate-buffered saline. Tumor growth was monitored every 3
days. Tumors were measured with a dial-caliper and volumes were
determined using the formula (width)2 length 0.52. Tumors were
selected for cryosurgery when their diameter measured 6–8 mm. In
tumor rechallenge experiments, mice were killed when tumors
reached a volume of 1500 mm3.
Cryosurgery
Mice were anesthetized by intraperitoneal injection of ketamine-HCl
(100 mg/kg). Cryosurgery was performed using an intermittent liquid
nitrogen spray (Cry-A-C device, Brymill, Ellington, CT). The spray
was emitted from a distance of 2–3 cm from the tumor at a 901 angle.
A three-cycle 30-second freeze/thaw regimen was performed to
ensure maximum tumor cell death. After the procedure, mice were
kept on a heating pad until they recovered from anesthesia. This
point in treatment was taken as day 0. Excisional treatment of the
tumor consisted of complete removal of the lesion with part of the
underlying muscle.
Imiquimod treatment
Immediately after cryosurgery, during 10 days, mice received topical
treatment with imiquimod. Imiquimod was obtained as a 5% cream
(AldaraTM, 3 M, Barcelona, Spain) in packets containing 12.5 mg of
imiquimod. The drug was applied daily to shaved skin at the tumor
site. Four mice per group were treated with a single packet of
imiquimod so that each mouse received approximately 25% of the
total active imiquimod agent present (3.125 mg). Control mice were
treated with vehicle control.
Rechallenge
Fifteen days after cryosurgery of tumors, mice were challenged by
subcutaneous injection on the contralateral flank with 3 104 B16/
OVA cells in 100 ml of phosphate-buffered saline. Some mice that
rejected the first rechallenge received a second, third, and even a
fourth rechallenge with B16OVA or B16F10 cells, inoculated on
days 90, 120, and 160 (Figure 3).
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Statistics
Overall survival after rechallenges was estimated according to the
Kaplan–Meier method. Comparison of group survival was calculated
using the log-rank test.
Tissue and sera processing
Spleen and lymph nodes were collected and cut into pieces. For
every group, tumors were dissected and specimens were fixed in
10% buffered formalin, embedded in paraffin, sectioned at 4–7 mm,
and stained with hematoxylin–eosin.
Proliferation assay and measurement of cytokine
production
Animals were killed and lymph node or spleens removed. Spleen
and lymph node cells were triturated and then plated in 96-well
plates at 8 105 cells/well with culture medium (RPMI 1640
supplemented with 10% fetal calf serum, 2 mM glutamine, 100 U/
ml penicillin, 100 mg/ml streptomycin, and 5 105 M 2-b-mercap-
toethanol) alone, or with 10 mM of OVA in a final volume of 0.25 ml.
Supernatants were collected after 48 hours of culture to measure
IFN-g production. Then, cells were pulsed with 0.5 mCi/well of [3H]-
thymidine for 18 hours and harvested. Thymidine incorporation was
determined in a scintillation counter (Topcount; Packard, Meridan,
CT). Finally, the stimulation index was calculated as the ratio of
response to OVA protein over mean response in the absence of
protein.
IFN-g production was measured by ELISA (Pharmingen, San
Diego, CA) according to the manufacturer’s instructions.
NK cell activity assay
NK cell activity of freshly harvested spleen cells was measured by a
chromium-release assay using YAC-1 and EL-4 as control targets.
YAC-1 and EL-4 were labeled with 50 mCi of Na2
51CrO4 for 1 hour.
Spleen cells with different ratios of target cells were plated in a
round-bottom 96-well plate. Cells were incubated for 4 hours.
Spontaneous release was determined by incubating only target cells
and maximum release was measured by standing target cells in
medium containing 1% Triton X-100. Supernatants were collected,
and the radioactivity released during incubation from lysed target
cells was measured. The percentage of specific lysis was calculated
using the following formula:
specific lysis ð%Þ ¼ðexperimental release spontaneous releaseÞ=
ðmaximum release spontaneous releaseÞ100
Measurement of CTL response
Spleen cells (8 106) were plated in 24-well plates and stimulated
with 2 ml of culture medium containing OVA protein (10 mM).
Cytotoxic activity was measured 5 days after initial culture using the
51Cr-release assay. B16-OVA and EL-4 (as control target) were
radiolabeled with 50 mCi of Na2
51CrO4 for 1 hour, washed three times
and incubated for 4 hours at different ratios. Spontaneous release
was determined by incubating only target cells and maximum
release was measured by standing target cells in medium containing
1% Triton X-100. Supernatants were collected, and the radioactivity
released during incubation from lysed target cells was measured. The
percentage of specific lysis was calculated using the following
formula:
specific lysis (%)¼ (experimental release–spontaneous release)/
(maximum release–spontaneous release) 100
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